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Background: Black men with prostate cancer are diagnosed at a younger age, present with more aggressive
disease, and experience higher mortality. We sought to assess pathological features and biochemical recurrence
(BCR) in young men undergoing radical prostatectomy (RP) to determine if there is a difference between black and
white men closer to the time of disease initiation.
Methods: We identified 551 white and 99 black men at a tertiary cancer center who underwent RP at ≤50 years of
age. Baseline and pathological features were compared between the two groups. Cox proportional hazards models
were utilized to examine the association of race and BCR, and Kaplan-Meier curves were generated to determine
biochemical recurrence-free survival (bRFS).
Results: There were no differences in median age at surgery, biopsy Gleason score, or comorbidity. Black men had
higher preoperative PSA (6.1 ng/ml vs 4.7 ng/ml, p = 0.004), but a greater percentage were cT1c (78% vs 63%),
compared to white men. On multivariate analysis, black men demonstrated significantly lower odds of non-organ
confined disease (OR 0.39; 95% CI: 0.18, 0.81; p = 0.01) and extracapsular extension (ECE) (OR 0.38; 95% CI: 0.18, 0.81,
p = 0.01), and had no difference in Gleason score upgrading and seminal vesicle invasion compared to white men.
There was no significant difference in bRFS in men with organ-confined disease; however, among men with locally
advanced disease black men trended towards greater BCR (p = 0.052). Black men had 2-year bRFS of 56% vs 75% in
white men.
Conclusions: In this single institution study, there does not appear to be a racial disparity in outcomes among
younger men who receive RP for prostate cancer. Black and white men in our cohort demonstrate similar bRFS
with pathologically confirmed organ-confined disease. There may be greater risk of BCR among black men locally
advanced disease compared to white men, suggesting that locally advanced disease is biologically more aggressive
in black men.
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Black men have the highest incidence of prostate cancer
and a 2.4-times greater mortality from prostate cancer
compared to white men in the US [1]. Additionally, pros-
tate cancer in black men tends to present at a younger age
with more adverse pathological characteristics such as* Correspondence: kelvin.a.moses@vanderbilt.edu
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vanced disease [2-5]. A significant focus of research into
this disparity is to identify the potential source(s). One
potential source may be that differences in treatment
received by black men may play a role in poorer out-
comes. Black men are less likely to receive definitive
therapy (surgery or radiation) vs androgen deprivation
therapy and are less likely to receive surgery, regardless of
stage at presentation [6-9]. It is unknown if treatment choice
is more influenced by patient or physician factors, though
both likely play a significant role [10-12]. Nevertheless,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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men that receive RP in terms of BCR and disease-free
survival [5,13,14].
A second hypothesis to explain the mortality disparity is
that prostate cancer biological behavior differs in black
men compared to white men. Sanchez-Ortiz et al. showed
that among men who underwent RP with cT1c disease
and similar biopsy characteristics, black men have greater
tumor volume, higher Gleason scores, and nearly 3 times
more tumor per ng/ml of serum PSA [15]. Similarly, other
groups have shown greater tumor volumes in black men
compared to white men with similar clinical characteris-
tics [16,17] which potentially could translate to greater
risk of BCR and disease-free survival [18].
Third, it has been postulated black men present with
later stage disease, and thus are at increased risk for
prostate cancer mortality. Some reasons for later stage
at presentation include lack of insurance [19], less
frequent or absent pre-diagnosis PSA testing [20], faster
growth rate of cancer from the time of initial disease
[17], and higher rates of obesity [21]. However, data
indicate that the overall stage shift seen in recent years
is now being observed in black men, which may serve to
improve survival outcomes [14,22].
We sought to compare the clinical features and rate of
BCR of men undergoing RP in a tertiary care center. We
analyzed men prior to age 50 to determine if differences
in prostate cancer behavior nearer to the time of initial
disease lead to poorer outcomes in black men. Pre-
operative PSA and stage, pathological features and the
rate of BCR were assessed, and bRFS was compared
between black and white men. We hypothesized that
younger black men with localized disease who receive
RP will achieve similar outcomes to white men.
Methods
After obtaining Memorial Sloan-Kettering Cancer Center
Institutional Review Board approval to access patient
data, we identified 741 prostate cancer patients aged 50
or less who self-identify as “black” or “white” race and
underwent a RP at MSKCC. Eighty-nine patients with
surgery dates prior to year 2000 with incomplete data
were excluded from the analysis. Two patients with
neoadjuvant hormone and radiation therapy were also
excluded from the analysis. The remaining 650 patients
constituted the study cohort.
The primary aim is to compare differences in adverse
pathological features between black and white men
50 years and younger. The age of 50 years was chosen as
the cutoff because, although some guidelines now recom-
mend earlier screening in black men, during the time
period that comprised this study this was the age at which
men are recommended to start PSA screening. For univar-
iate analysis, we utilized the t-test for continuous variables,and Chi-square analysis for categorical variables. We used
logistic regression models to assess whether black men
have a higher probability of adverse pathological features
(non-organ confined disease, seminal vesicle invasion
(SVI), ECE, upgrade in Gleason score between biopsy and
pathology) than white men. An upgrade in Gleason score
was defined as an initial score of 6 or lower to 7 or higher
on pathology or an initial score of 7 to 8 or higher on
pathology. Biopsy Gleason scores of 8 were excluded from
the model predicting upgrade in Gleason score as there is
no higher Gleason category. The adverse outcomes were
examined separately in logistic regression models adjusted
for race along with important preoperative characteristics
of the tumor including preoperative PSA, biopsy Gleason
score, and clinical stage. As such, our question specifically
pertains to whether black men have more aggressive
tumors. No patients with biopsy Gleason grades of 6 or
lower had lymph node involvement (LNI), and they were
subsequently excluded from that analysis. Additionally,
because so few patients had LNI, this analysis was limited
to the univariate setting.
We conducted additional analyses to explore if race
was associated with biochemical recurrence using Cox
proportional hazards regression models. We evaluated
the association between race and BCR adjusting for pre-
operative PSA, biopsy Gleason score, and clinical stage.
A separate model was created adjusting for preoperative
PSA, pathologic Gleason score and pathologic stage
(organ- confined vs. locally advanced). bRFS curves were
calculated separately for organ- confined and locally
advanced disease using Kaplan-Meier methods and dif-
ferences in survival times compared using the log –rank
test. All statistical analyses were conducted using STATA
11.0 (Stata Corp., College Station, TX, USA).
Results
Table 1 summarizes baseline and pathologic characteris-
tics of 99 black and 551 white patients under 50 who
underwent RP between January 2000 and February 2011.
There was a significant difference between the two groups
in terms of preoperative clinical stage, with black men
having a higher percentage of cT1c disease compared to
white men. Black men did have significantly higher pre-
operative PSA (6.1 ng/ml vs. 4.7 ng/ml, p = 0.004)), and a
greater percentage of Black men had CCI >2; however,
there were no differences in median age at surgery, or bi-
opsy Gleason grade. There were no significant differences
in overall pathological characteristics between the two
groups in terms of Gleason score, extracapsular extension,
lymph node involvement, or seminal vesicle invasion.
After adjusting for preoperative PSA, biopsy Gleason
grade, and clinical stage, black race had a highly protective
effect for non-organ confined prostate cancer in men under
50 (Table 2). The odds of non-organ confined disease at the
Table 1 Preoperative and pathologic characteristics of
men younger than 50 undergoing RP (n = 650)
Black N = 99 White N = 551 p-value
Preoperative characteristics
Age at surgery 47 (45, 48) 47 (45, 49) 0.08
Preoperative PSA 6.1 (4.0, 8.3) 4.7 (3.0, 6.7) 0.004
Biopsy Gleason score 0.3
≤6 51 (53%) 329 (61%)
7 38 (40%) 177 (33%)
≥8 7 (7%) 31 (6%)
Clinical Stage 0.03
T0, T1a, T1b 1 (1%) 3 (1%)
T1c 76 (78%) 347 (63%)
T2a 11 (11%) 113 (21%)
T2b 7 (7%) 45 (8%)
≥T2c 2 (2%) 31 (7%)
Charlson comorbidity score 0.04
≤2 5 (5%) 20 (4%)
3-5 73 (74%) 463 (84%)
≥6 21 (21%) 68 (12%)
Pathologic characteristics
Pathologic Gleason score 0.6
≤6 35 (35%) 219 (40%)
7 58 (59%) 294 (54%)
≥8 6 (6%) 30 (6%)
Extracapsular extension 14 (14%) 124 (23%) 0.06
Lymph node involvement 0.4
Positive 2 (2%) 28 (5%)
Negative 88 (89%) 483 (88%)
Not performed 9 (9%) 40 (7%)
Seminal vesicle invasion 5 (5%) 25 (5%) 0.8
All values are median (IQR) or frequency (proportion).
Table 2 OR of adverse pathological findings for black
race (vs. white race)
Adverse pathological outcome OR 95% CI P-value
Non organ confined disease 0.39 0.18,0.81 0.01
Extracapsular extension 0.38 0.18,0.81 0.01
Seminal vesicle invasion 0.93 0.30,2.93 0.9
Lymph node involvement* 0.36 0.08,1.53 0.16
Upgrade in Gleason score 0.97 0.54,1.74 0.9
Adjusted for preoperative PSA, biopsy Gleason grade, and clinical stage.
*Univariate analysis in biopsy Gleason scores of 7 or more only.
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0.01), in other words, among men under 50, black race was
associated with a statistically significant 60% reduction in
the odds of non-organ confined disease for a given stage,
grade, and PSA. When non-organ confined disease was
stratified by ECE, SVI, and LNI, we found black race was
only significantly associated with lower odds of ECE (OR
0.38, 95% CI: 0.18, 0.81, p = 0.01). There was no significant
association between race and SVI or LNI among younger
men (p = 0.9 and p = 0.16 respectively). The 95% confidence
intervals for both LNI and SVI include the estimate for non-
organ confined disease, so we do not see evidence of a dif-
ferential effect of race on SVI versus LNI versus ECE. Black
race also did not have a significant effect on upgrade in
Gleason score in men under 50 (OR 0.97, 95% CI: 0.54, 1.74
p = 0.9).
Given the significant association between race and
pathologic stage, we explored recurrence outcomes be-
tween black and white patients. At last follow up, 59
patients recurred and median follow up in patients with-
out biochemical recurrence was 3.5 years. After adjust-
ing for preoperative variables, there was no evidence
that race was significantly associated with bRFS (p = 0.9).
We conducted Kaplan-Meier analyses to investigate if
a survival difference among black and white patients is
apparent in both organ-confined and locally advanced
disease. There was no statistically significant difference
in bRFS between white and black patients with organ-
confined disease (p = 0.4 by the log-rank test, Figure 1a).
Kaplan Meier survival curves demonstrate black patients
with locally advanced disease were at a greater risk of an
earlier BCR than white patients (Figure 1b) and this
result was close to statistical significance (p = 0.052 by
log-rank test). This was also a small sample of black
patients with 7 recurrences among 15 black patients
with locally advanced disease. The 2-year bRFS was
56% (95% CI 27%, 78%) among patients of black race and
75% (95% CI 66%, 82%) among patients of white race.
Discussion
In this study of men younger than 50 years of age under-
going RP for clinically localized prostate cancer, we show
that black race is associated with lower odds of non-
organ confined disease and ECE. This finding may not
necessarily be a biological effect, but potentially a reflec-
tion of more aggressive screening of black men in this
cohort. This is demonstrated by the difference in presen-
tation of cT1c disease (77% black vs 63% white), and a
larger proportion of black men having lower sub-
classification of T2a and T2b than white men (90% vs
94%). Our findings are in keeping with data from others
showing favorable outcomes in younger men undergoing
RP [3]. We also show that while black and white men
with localized disease have no difference in BCR, black
Figure 1 Kaplan-Meier curve for bRFS in patients with a) organ
confined disease (p = 0.4), and b) locally advanced disease
(p = 0.052). (Black = solid, White = dashed).
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(56% vs 75%).
A significant proportion of black and white men in
our cohort presented with cT1c disease. The use of PSA
screening and refinement of guidelines has led to a
significant stage shift over time in all men, though black
men have lagged in the percentage of men diagnosed
with regional or distant disease [23]. Bianco et al. re-
ported an improvement in clinical stage, preoperative
PSA and biopsy Gleason score in men with prostate
cancer treated after 1996 [14]. Black men in the group
treated after 1996 had no significant difference in cancer
recurrence-free survival compared to white men, and
demonstrated a 20% increase in disease-free survival. In
contrast, prior to 1996, black race was an independent
predictor for pathological Gleason score and stage.
Therefore, black men have derived a documented sur-
vival benefit by the stage shift seen in the PSA era. Fur-
ther evidence that appropriate screening can improve
clinical stage at presentation comes from Jones et al.
who showed a significant reduction in the association of
black race and risk of advanced disease in men whoreceived digital rectal examination and/or PSA testing
[24]. The risk of advanced disease was not completely
mitigated with PSA and digital rectal examination, nor
was it when controlling for other sociodemographic
factors, thus indicating a difference in the biological
behavior of prostate cancer in black men.
Our study demonstrates that black men had similar or
better pathologic outcomes compared to white men
younger than 50 when receiving RP. Other groups have
demonstrated improved outcomes in black men who
have RP as their primary mode of treatment. In a study
of 2407 men following RP for low-risk prostate cancer,
Resnick et al. found no significant differences in BCR,
locally advanced disease, or risk of disease upgrading
between black and white men [13]. The results were not
stratified by age so it is unknown whether men younger
than 50 demonstrate similar results, but their findings
suggest that black men with low risk disease who have
RP can achieve equivalent results to white men. Under-
wood et al. showed similar cancer-free survival between
black and white men who had RP, when matched for
stage and grade [25]. Black men in their overall cohort
were significantly younger, which suggests a potential
benefit to earlier screening and aggressive treatment as a
way of reducing the mortality disparity. These results are
encouraging; however, black men are less likely to have
RP as the primary treatment modality and more likely to
have RT or ADT than whites with similar stage and
grade [6,26].
We show that black men with locally advanced disease
may be at greater risk for BCR than white men who have
received the same treatment, suggesting that black men
may display more biologically aggressive tumors at higher
stages. In a study of men undergoing RP at Wayne State
University, Wood et al. showed no difference in the rate of
organ-confined disease after RP between black and white
men (76.3% vs 71.0%) [27]. However, they reported a 12%
lower absolute difference in bRFS 5 years after RP in black
men despite a significant shift in disease characteristics at
presentation. This difference in bRFS was similar to that
seen earlier in the PSA era (11%). Their data suggest
aggressive biological behavior influences long-term out-
comes, particularly in higher stage patients. This is
confirmed in their analysis of 612 patients who underwent
RP between 1991 and 1995, comparing the rate of BCR
between black and white men at a mean of 34 months
follow-up [28]. Similar to the findings of this study, the
authors found that black men with locally advanced dis-
ease were more likely to experience BCR, but not those
with organ-confined disease. They also found a trend to-
wards a greater percentage of high grade Gleason patterns
in black men. Using data from their institution and SEER,
Powell et al. have suggested that although tumor charac-
teristics at disease initiation in black and white men are
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gress to advanced or metastatic disease earlier in the
course of the disease [17]. In fact, black men demon-
strated advanced or metastatic disease at a 4:1 ratio com-
pared to white men. This may explain why black men
with organ-confined disease have similar postoperative
outcomes to white men, as the disease is likely closer to
that seen at initiation. However, faster growth/transform-
ation is clearly recognized in black men, which has led to
a search for genetic variants or other molecular markers
for aggressive disease in men of different ethnic back-
grounds. Recent studies have yielded some clues to a bio-
logical basis of aggressive tumor features. Haiman et al.
performed a genome wide study in men of African ances-
try and found a significant association with a variant of
chromosome 17q21 in prostate cancer cases rarely seen in
men of other populations [29]. Other potential genetic
targets, such as 11q22 and Xq21, have been identified by
genome-wide linkage analysis in the African-American
Hereditary Prostate Cancer study [30]. The use of this
large study of African-American families with at least four
affected member will be critical to identify targets for risk
of prostate cancer, and potentially may help predict risk
for aggressive prostate cancer growth.
Our results are to be interpreted in the context of
some limitations. MSKCC is a tertiary/quaternary refer-
ral center, so results from our cohort are not necessarily
applicable to the general population. In particular, black
men who receive treatment are likely to have higher so-
cioeconomic status compared to other studies completed
in underinsured/uninsured populations, and likely were
more aggressively screened than men with lower socio-
economic status. Additionally, the overall number of
patients is relatively small, especially among those who
experienced BCR. The a priori age limit we set for the
purposes of this study restricts the numbers of patients
available for study, which is not likely to be different
than other institutions that treat large numbers of pa-
tients. However, our results are bolstered by the ability
to compare a relatively similar cohort of black and white
men, which strengthens the conclusions we make re-
garding the improved outcomes of black men who re-
ceive RP.
Conclusions
We show that younger black men who receive RP for
clinically localized prostate cancer can achieve similar
outcomes compared to white men. Black men were at no
additional risk of Gleason upgrading compared to young
white men. Although we demonstrate an association of
black race with lower odds of having locally advanced dis-
ease, these findings likely reflect the benefit of aggressive
screening and treatment. Importantly, we show that black
men with pathologically locally advanced disease may beat higher risk for biochemical recurrence than white men
after RP. These results suggest that progression to later
stage disease poses an increased risk for poorer outcomes
in black men. Future studies on early screening in black
men combined with aggressive definitive therapy should
be conducted to assess the impact of stage at presentation
on BCR and survival. Additionally, in men with locally
advanced disease, comparison of specific genetic targets
may explain differences in the biological behavior of
prostate cancer in black men.
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